At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TPST Tempest Therapeutics Inc.
Pre-Mkt 05-18 05:06:55 EDT
1.83
-0.26
-12.44%
High2.00Low1.83Vol271.56K
Open2.00D1 Closing2.09Amplitude8.37%
Mkt Cap27.10MTradable Cap17.81MTotal Shares14.81M
T/O512.06KT/O Rate2.79%Tradable Shares9.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Tempest net loss widens 155% to $27.7 million in Q1 2026
Reuters  ·  05-15
Tempest net loss widens 155% to $27.7 million in Q1 2026
Tempest Therapeutics Q1 net loss widens on asset acquisition costs
Reuters  ·  05-15
Tempest Therapeutics Q1 net loss widens on asset acquisition costs
Tempest Therapeutics Q1 Operating Income USD -27.719 Million
THOMSON REUTERS  ·  05-15
Tempest Therapeutics Q1 Operating Income USD -27.719 Million
Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Dow Jones  ·  05-15
Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Tempest Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Reuters  ·  05-08
Tempest Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Tempest says TPST-2003 dual-target CAR-T hits 100% complete response in Phase 1 trials
Reuters  ·  05-06
Tempest says TPST-2003 dual-target CAR-T hits 100% complete response in Phase 1 trials
Jakarta, Danantara Sign Rp17.4 Trillion Waste-to-Energy Deal
Tempo  ·  05-05
Jakarta, Danantara Sign Rp17.4 Trillion Waste-to-Energy Deal
Tempest to present TPST-2003 clinical update at ISCT annual meeting
Reuters  ·  04-29
Tempest to present TPST-2003 clinical update at ISCT annual meeting
Tempest Therapeutics provides update on development of TPST-2003
TIPRANKS  ·  04-22
Tempest Therapeutics provides update on development of TPST-2003
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
GlobeNewswire  ·  04-22
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
Press Release: Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
Dow Jones  ·  04-14
Press Release: Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
Tempest Therapeutics Inc - Company Will Not Receive Proceeds From Sale of Shares by Selling Stockholders - SEC Filing
THOMSON REUTERS  ·  04-02
Tempest Therapeutics Inc - Company Will Not Receive Proceeds From Sale of Shares by Selling Stockholders - SEC Filing
Tempest Therapeutics Inc - Prospectus Filed for Resale of up to About 2.8 Mln Shares Including Warrants - SEC Filing
THOMSON REUTERS  ·  04-02
Tempest Therapeutics Inc - Prospectus Filed for Resale of up to About 2.8 Mln Shares Including Warrants - SEC Filing
Tempest Therapeutics files to sell 2.78M shares of common stock for holders
TIPRANKS  ·  04-02
Tempest Therapeutics files to sell 2.78M shares of common stock for holders
Tempest Therapeutics files to sell 8.27M shares of common stock for holders
TIPRANKS  ·  03-31
Tempest Therapeutics files to sell 8.27M shares of common stock for holders
Tempest Therapeutics Inc - Offers up to 8.27 Mln Shares of Common Stock for Resale by Selling Stockholders - SEC Filing
THOMSON REUTERS  ·  03-31
Tempest Therapeutics Inc - Offers up to 8.27 Mln Shares of Common Stock for Resale by Selling Stockholders - SEC Filing
BRIEF-Tempest Reports Year End 2025 Financial Results And Provides Business Update
Reuters  ·  03-30
BRIEF-Tempest Reports Year End 2025 Financial Results And Provides Business Update
Tempest Therapeutics Inc - Appoints Matt Angel as CEO and President
THOMSON REUTERS  ·  03-30
Tempest Therapeutics Inc - Appoints Matt Angel as CEO and President
Tempest Therapeutics Inc - Reports Net Loss of $26.3 Mln and Net Loss per Share of $6.33 for 2025
THOMSON REUTERS  ·  03-30
Tempest Therapeutics Inc - Reports Net Loss of $26.3 Mln and Net Loss per Share of $6.33 for 2025
Tempest Therapeutics Inc - Announces Positive Interim Data From Redeem-1 Phase 1/2a Trial of Tpst-2003
THOMSON REUTERS  ·  03-30
Tempest Therapeutics Inc - Announces Positive Interim Data From Redeem-1 Phase 1/2a Trial of Tpst-2003

Introduction

Company Name.
Tempest Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Issue price:
--